Mutants of Lactobacillus kefir short-chain alcohol dehydrogenase, used here as ketoreductases (KREDs), enantioselectively reduce the pharmaceutically relevant substrates 3-thiacyclopentanone and 3-oxacyclopentanone. These substrates differ by only the heteroatom (S or O) in the ring, but the KRED mutants reduce them with different enantioselectivities. Kinetic studies show that these enzymes are more efficient with 3-thiacyclopentanone than with 3-oxacyclopentanone. X-ray crystal structures of apo-and NADP + -bound selected mutants show that the substrate-binding loop conformational preferences are modified by these mutations. Quantum mechanical calculations and molecular dynamics (MD) simulations are used to investigate the mechanism of reduction by the enzyme. We have developed an MD-based method for studying the diastereomeric transition state complexes and rationalize different enantiomeric ratios. This method, which probes the stability of the catalytic arrangement within the theozyme, shows a correlation between the relative fractions of catalytically competent poses for the enantiomeric reductions and the experimental enantiomeric ratio. Some mutations, such as A94F and Y190F, induce conformational changes in the active site that enlarge the small binding pocket, facilitating accommodation of the larger S atom in this region and enhancing S-selectivity with 3-thiacyclopentanone. In contrast, in the E145S mutant and the final variant evolved for large-scale production of the intermediate for the antibiotic sulopenem, R-selectivity is promoted by shrinking the small binding pocket, thereby destabilizing the pro-S orientation. directed evolution | crystallographic structures | molecular dynamics | theozyme | enantioselectivity B iocatalysis is a common method of stereoselective ketone reduction (1). This approach often replaces multistep syntheses and uses renewable, biodegradable, and nontoxic reagents and mild conditions (2). Ketoreductases (KREDs), the most commonly used enzymes in industrial pharmaceutical synthesis (3), reduce a wide range of ketones to alcohols with high chemoselectivity and stereoselectivity. These enzymes have been engineered to synthesize alcohols as intermediates for the production of atorvastatin (Lipitor), montelukast (Singulair), and atazanavir (Reyetaz) (4).Small and almost symmetrical ketones, such as prochiral cyclopentanones, are attractive substrates that are difficult to reduce asymmetrically by chemical methods (5, 6). In particular, the enantiopure chiral alcohols derived from 3-oxacyclopentanone (1) and 3-thiacyclopentanone (2) are used in the synthesis of the pharmaceutical agents fosamprenavir and sulopenem, respectively (Fig. 1). Through a directed evolution (DE) program, Codexis, Inc. engineered a KRED obtained from Lactobacillus kefir for the reduction of 3-thiacyclopentanone (2) for the large-scale production of the antibiotic sulopenem. L. kefir KRED (WT) belongs to the short-chain dehydrogenase/reductase (SDR) family (7,8). Via DE, a variant containing 10 mutati...